This study builds on data that high-density lipoprotein (HDL) has a number of potentially beneficial effects including directly modulating glucose metabolism through multiple mechanisms. The primary objective of this study is to determine the effects of RVX000222 on postprandial plasma glucose in male individuals with impaired fasting glucose (IFG) or impaired glucose tolerance (IGT), during a frequently sampled oral glucose tolerance test (OGTT).
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
20
capsule, 200 mg, administer with food, 100 mg twice daily 10-12 hrs apart, 31-35 days
capsule, administer with food, twice daily 10-12 hrs apart, 31-35 days
Baker IDI Heart and Diabetes Institute 75 Commercial Road,
Melbourne, Victoria, Australia
Change in plasma glucose following treatment with RVX000222 compared to placebo
The change in postprandial plasma glucose, defined as area under the glucose curve (AUGC) during a frequently sampled OGTT following RVX000222 treatment for 29-33 days as compared to placebo.
Time frame: 29-33 days
Change in insulin secretion and insulin sensitivity following treatment with RVX000222 compared to placebo
The change in indices of insulin secretion (β-cell function) and insulin sensitivity during a frequently sampled OGTT following RVX000222 treatment for 29-33 days as compared to placebo.
Time frame: 29-33 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.